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RepoRt
Alloantibody reactivity is approximately 0.3 percent in blood 
donors worldwide. The present study established total alloanti-
body and clinically significant alloantibody (CSAA) frequencies in 
all Colombian Red Cross National Blood Bank donors (almost all 
donors were Colombian). The probability of these alloantibodies 
reacting with a specific antigen in the general population was also 
determined, focusing on male CSAA data because routine practice 
in this blood bank is to discard female plasma components to 
avoid transfusion-related acute lung syndrome. Total blood donor 
population between 2007 and 2009 was 60,309 (55.4% male and 
44.6% female). Cells I and II were used for alloantibody screening 
following the Autovue protocol. Positive samples were identified 
by red blood cell (RBC) panels (Panel A, Panel B, and Panel C, 
Ortho Clinical Diagnostics, Raritan, NJ). Alloantibody and CSAA 
frequency were established for both sexes. The database for RBC 
antigens estimated for the Colombian population was used for 
calculating the probability of antigen-antibody reaction from 
donors in this blood bank. Total alloantibodies (438) and CSAA 
frequency (138) were significantly higher in women than men (p 
< 0.01). Seventy-four percent of CSAA found in women came from 
the Rh blood group system. Calculated probability of generating 
antigen-antibody reaction using plasma only from male donors 
was estimated as 20.55 episodes for every 100,000 donations, 
and the probable number of events per year was 1.48. Meanwhile, 
considering all blood components from male and female origin, 
the calculated probability of antigen-antibody reaction was 
123.54 episodes for every 100,000 donations and 28.67 probable 
events per year. The data presented here do not represent strong 
support for the routine screening of alloantibodies in blood 
donors. Immunohematology 2012;28:60–6.
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Blood component transfusion can produce a series 
of immunologic effects, the most serious ones being 
alloimmunization, allergic reactions, febrile reactions, and 
immunosuppression.1–3 Red blood cell (RBC) antigen immuno-
genicity is the likelihood of an antibody being generated in a 
blood recipient. It depends on exposure route, the recipient’s 
medical condition (inflammation, immunosuppression),4 and 
history of previous alloimmunization (which promotes new 
alloimmunization).5,6 Once exposed to an antigen, the immune 
system can develop antibodies, called regular when they are 
generated against the antigens of the ABO blood group system 
and irregular or alloantibodies (AAs) when they are generated 
against other RBC blood group systems.7
AA screening is a test performed by blood banks and 
transfusion services for reducing minor incompatibility.7 
AA seroprevalence in blood donors around the world has 
been estimated as being 0.3 percent (0.2%–0.8%).7 Some 
reports from Latin America have shown similar values: 0.19 
percent8 in Costa Rica and 0.34 percent in Brazil.9 Colombian 
regulations10,11 make this test mandatory for all  units of blood 
collected, without taking prevalence in national blood donors 
into account.
A previous study on a Colombian population12 found 
0.39 percent RBC AA prevalence, almost half of which were 
considered clinically significant alloantibodies (CSAAs) 
because they were related to hemolytic transfusion reactions 
(HTR) or shortened  RBC survival.12,13 The CSAAs found, in 
order of frequency, were anti-D, -E, -K, -M, -S, and -k. On the 
other hand, a 1993 study of 30,259 men involved in paternity 
suits from all regions of Colombia14 documented RBC antigen 
prevalence for the eight most frequent blood group systems; 
the authors concluded that RBCs presented a predominantly 
Caucasian phenotype. Likewise, the Colombian National 
Institute of Health issued a consolidated report in 1999 
regarding 338,063 blood units that were classified for ABO 
and D blood group antigens.15 Both series are summarized in 
Table 1.
The present paper has two components: the first is a 
description of RBC AA frequency in Colombian Red Cross 
National Blood Bank (CRCNBB) blood donors in Bogota 
(2007–2009). A selection of CSAAs was also taken and 
organized by sex. The second component is the calculation 
of the likelihood of generating HTR or reduced RBC survival, 
using data from Table 1.
Study Design and Methods
Study Population
Total donations received between 2007 and 2009 were 
60,309 (55.4% male and 44.6% female).
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Screening Assay and RBC AA Identification
A retrospective search was conducted for whole-blood 
donations made between January 2007 and July 2009 to 
establish RBC AA prevalence in our donor population. AA 
screening was done using the Autovue system with the column 
agglutination method (polyclonal anti-IgG -C3d) and a 2-cell 
screen (Surgiscreen, Ortho Clinical Diagnostics, Raritan, NJ). 
AAs were identified in units having positive AA screening, 
using panels (Panel A, Panel B, and Panel C, Ortho Clinical 
Diagnostics). The following AAs were identified using those 
panels: anti-Lea, -Leb, -D, -C, -c, -E, -e, -Fya, -Fyb, -K, -k, -Jka, 
and -Jkb.
Nomenclature
We defined the following terms:
•	 Alloantibodies	 against	 low-prevalence	 antigens:	 those	
with a positive screening test but having a negative 
identification test result with panel A.
•	 Cold	antibodies	(CAs):	antibodies	reactive	below	37°C.
•	 Nonspecific	IgG	antibodies	(NIAs):	those	units	having	a	
positive screening test and complete agglutination in all 
cells from panel A.
•	 Non–clinically	 significant	 alloantibodies	 (NCSAAs):	
those not related to disease, HTR, or reduced RBC 
survival.
•	 Minor	 incompatibility:	 hemolysis	 after	 destroying	 a	
percentage of the patient’s RBCs by antibodies present 
in a plasma unit.
Calculating Minor Incompatibility Likelihood for a 
Single Transfusion
The likelihood of generating an antibody-antigen 
reaction in a single plasma transfusion from male donors 
was established using RBC antigen frequencies estimated 
previously for Colombian people14 and the frequency of AAs 
found in our blood donors. This calculation was performed 
using only male donors because our standard practice is to 
discard female fresh-frozen plasma units without taking 
into account the donor’s history of pregnancies to reduce the 
incidence of transfusion-related acute lung injury (TRALI).16,17 
International reports suggest a 10 to 20 percent prevalence of 
antibodies to leukocyte antigens in female blood donors with 
a history of pregnancy and 1 to 5 percent in male donors as 
the main risk factor for TRALI (odds ratio, 15),16 but it is not 
a regular practice in CRCNBB to perform leukocyte antibody 
screening. Moreover, as the demand for plasma components 
can be met with only male donors, this is a standard CRCNBB 
policy. Antigen-antibody reaction probability was calculated as 
being the likelihood of finding an AA in plasma donors and the 
corresponding RBC antigen in the recipient. Calculations were 
made as follows: the found antibody frequency was divided by 
the total number of donors, and the result was then multiplied 
by 100,000 transfusions to yield the antibody probability. 
Antigen-antibody reaction probability was calculated by 
multiplying antibody probability by 100,000 transfusions to 
yield the antigen likelihood in the population. The antigen 
probabilities we used in this calculation were those in Table 1.
Statistics
The χ2 test was used to determine the significance of sex-
related AA frequency with a significance level of 95 percent. 
AAs and RBC antigens are expressed as percentages of the 
total population.
Table 1. Relevant red blood cell antigen frequency found in 
Colombian males and Colombian blood donors*
System Phenotype
Frequency in  
males (%)
Frequency in  
blood donors  
(male and female) (%)














Kell (ISBT 006) K+k– 0.06
K+k+ 3.63
K–k+ 96.29
Duffy (ISBT 008) Fy(a+b–) 30.86
Fy(a+b+) 39.04
  Fy(a–b+) 26.61
  Fy(a–b–) 3.46




*Data obtained from Sandoval C et al.14 and Beltran M et al.15
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Results
During the period being studied (2007–2009) there were 
60,309 whole-blood donations, and 438 AAs were found 
(0.73%), 66.7 percent of them in female blood donors and 33.3 
percent in male donors. The CSAAs were 140 (31.96%) and 
NCSAAs were 300 (68.5%) of those identified. Our results 
showed that the three AAs most frequently found in blood 
donors corresponded to NCSAAs; the most common AA found 
in blood donors (anti-Lea) had similar sex distribution, as did 
anti-S (not significant). The other AAs had a clear tendency to 
be more prevalent in women, most of them being classified as 
CSAAs, such as anti-D or -C (Table 2).
There were 12 cases in which two AAs were found in the 
same donor during the period being studied. Six of them were 
male donors having the following combinations: one anti-Lea/
CA; three anti-Lea,-Leb; one anti-Lea/NIA, and one anti-Lea, 
-Jka. Six female donors had the following combinations: three 
anti-D,-C, one anti-c,-E, and two anti-D,-E. It is worth noting 
that all AAs found in these women belonged to the Rh blood 
group system (ISBT 004).
Probability of Generating Antigen-Antibody Reaction 
in a Recipient
Tables 3 to 5 present the calculated probability of an 
antigen-antibody reaction, using fresh-frozen plasma (male 
donors only), platelets, and cryoprecipitate, respectively.
Discussion
Screening for AAs in every blood donor is mandatory for 
all Colombian blood banks but not in countries such as the 
Netherlands, United Kingdom, or United States.7,18,19 In these 
countries there is a policy of specific screening in certain 
populations considered at risk, such as multiply-transfused 
patients or intrauterine transfusions. Although not required, 
most if not all blood centers in the United States are routinely 
screening blood donations for serum or plasma AAs. This may 
be because U.S. donor centers try to identify those donors 
having AAs of high enough titer for use in typing antisera 
in serologic investigations. The supposed aim of mandatory 
screening in Colombia, according to the regulations,10,11 is to 
reduce the risk of AAs that may potentially cause early and 
delayed HTR in blood recipients, as well as shortened RBC 
survival. However, the evidence for serious adverse outcomes 
resulting from the transfusion of AAs other than ABO and Rh 
blood group antibodies contained in donor units to individuals 
that would, by chance, have the corresponding antigen(s) 
is lacking in the literature. Additionally, one has to consider 
that after transfusion these AAs would be diluted, making 
it unlikely that they would cause the recipient a detectable 
problem (Tables 3–6). Also, it is important to take into account 
that most if not all blood is now transfused as RBCs, having 
very little plasma.
The results in our donor population showed a 0.70 percent 
AA prevalence, which is higher than other reports.7,8,9,13 Of the 
AAs reported, a third (0.2%) were considered CSAAs (anti-D, 
-C, -c, -E, -M, -S, -Fya, -Fyb, -Jka, and -Jkb).12,13 As expected, 
in female donors the AA frequency was three times as high as 
in males,7,20 mainly reflecting the presence of anti-D. Previous 
results have shown that RBC AA origin is related to history of 
previous transfusions and pregnancy.13,20 Likewise, 80 percent 
of CSAAs were found in female donors; 65% of them belonged 
to the Rh blood group.21,22
Similarly, anti-K was the third CSAA found in our 
blood donor population; there was no statistical significance 
between sexes in frequency. This AA is the primary cause 
of hemolytic disease of the newborn (HDN) and HTR in 
other countries.23–25 Nevertheless, the estimated frequency 
of dominant homozygous and heterozygous phenotypes in 
Colombia is close to 3.7 percent.14 That is, we found a frequency 
of 3.8 cases per 10,000 patients for every unit transfused, 
which together with the previous considerations about the 
antigen-antibody reaction reinforces the low probability of 
experiencing these events. On the other hand, anti-M is rarely 
associated with HDN or HTR,26,27 even when its expression 
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Table 2. The frequency of alloantibodies in the donor population 
and their relationship to sex
Alloantibody Number % Total Females % F* Males % M* p value
Anti-Lea 137 31.28 68 49.64 69 50.36
AALFAs 73 16.67 48 65.75 25 34.25 <0.1
Cold antibodies 61 13.93 34 55.74 27 44.26
Nonspecific IgG 13 2.97 11 84.62 2 15.38 <0.1
Anti-Leb 14 3.20 8 57.14 6 42.86
Anti-D† 53 12.10 50 94.34 3 5.66 <0.05
Anti-E† 25 5.71 20 80.00 5 20.00 <0.05
Anti-K† 23 5.25 13 56.52 10 43.48
Anti-M† 13 2.97 6 46.15 7 53.85
Others† 26 6.0 22 100.00 4 <0.001
Total 438 100.00 280 63.93 158 36.07 <0.05
*F = female; M = male.
†Indicates alloantibodies considered clinically significant alloantibodies. The 
probability value represents the difference by sex.
AALFA = alloantibodies against low-prevalence antigens.
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Table 3. Estimated probability of antigen-antibody reaction based on 60,309 donations screened for alloantibodies, using plasma only 




Ab frequency × 100,000 
units
Ag probability per 100,000 
Colombian inhabitants
AAR probability × 100,000 
units
Probable number of 
events per year
Units required for 
generating 1 AAR Cases per year
Anti-D 7152 4.97 0.9421 4.69 0.34 21,338 1 each 2.98 years
Anti-K 7152 16.58 0.0369 0.61 0.04 163,439 1 each 22.85 years
Anti-E 7152 8.29 0.4132 3.43 0.25 29,191 1 each 4.08 years
Anti-M 7152 11.61 0.8653 10.04 0.72 9957 1 each 1.39 years
Anti-S 7152 3.32 0.5372 1.78 0.13 56,133 1 each 7.85 years
Total 20.55 1.48
AA = alloantibody; Ab = antibody; Ag = antigen; AAR = antigen-antibody reaction.
Table 4. Estimated probability of antigen-antibody reaction based on 60,309 donations screened for alloantibodies, using platelets from 




Ab frequency × 100,000 
units
Ag probability per 100,000 
Colombian inhabitants
AAR probability × 100,000 
units
Probable number of 
events per year
Units required for 
generating 1 AAR Cases per year
Anti-D 5228 87.88 0.9421 82.79 4.33 1208 1 each 0.23 years
Anti-K 5228 38.14 0.0369 1.41 0.07 71,060 1 each 13.59 years
Anti-E 5228 41.45 0.4132 17.13 0.9 5838 1 each 1.11 years
Anti-M 5228 21.56 0.8653 18.65 0.98 5361 1 each 1.02 years
Anti-S 5228 6.63 0.5372 3.56 0.19 28,066 1 each 5.37 years
Total 123.54 6.47
AA = alloantibody; Ab = antibody; Ag = antigen; AAR = antigen-antibody reaction.
Table 5. Estimated probability of antigen-antibody reaction based on 60,309 donations screened for alloantibodies, using cryoprecipitate 




Ab frequency × 100,000 
units
Ag probability per 100,000 
Colombian inhabitants
AAR probability × 100,000 
units
Probable number of 
events per year
Units required for 
generating 1 AAR Cases per year
Anti-D 1317 87.88 0.9421 82.79 1.09 1208 1 each 0.92 years
Anti-K 1317 38.14 0.0369 1.41 0.02 71,060 1 each 59.95 years
Anti-E 1317 41.45 0.4132 17.13 0.23 5838 1 each 4.44 years
Anti-M 1317 21.56 0.8653 18.65 0.25 5361 1 each 4.07 years
Anti-S 1317 6.63 0.5372 3.56 0.05 28,066 1 each 21.31 years
Total 123.54 1.64
AA = alloantibody; Ab = antibody; Ag = antigen; AAR = antigen-antibody reaction.
Table 6. Estimated probability of antigen-antibody reaction based on 60,309 donations screened for alloantibodies, using red blood cell 




Ab frequency × 100,000 
units
Ag probability per 100,000 
Colombian inhabitants
AAR probability × 100,000 
units
Probable number of 
events per year
Units required for 
generating 1 AAR Cases per year
Anti-D 23,204 87.88 0.9421 82.79 19.21 1208 1 each 0.05 years
Anti-K 23,204 38.14 0.0369 1.41 0.33 71,060 1 each 3.06 years
Anti-E 23,204 41.45 0.4132 17.13 3.97 5838 1 each 0.25 years
Anti-M 23,204 21.56 0.8653 18.65 4.33 5361 1 each 0.23 years
Anti-S 23,204 6.63 0.5372 3.56 0.83 28,066 1 each 1.21 years
Total 123.54 28.67
AA = alloantibody; Ab = antibody; Ag = antigen; AAR = antigen-antibody reaction.
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begins in erythroid precursors.26 The global frequency of M 
is 75 percent; hence, 25 percent of the population lacks M; 
such individuals are able to generate anti-M when they are 
exposed to the antigen. However, the frequency of anti-M was 
only 0.02 percent in this population, reflecting perhaps a low 
immunogenic power of this antigen.
Regular Antibodies Compared With Irregular 
Antibodies
Old transfusion practices used whole blood from 
universal group O donors, and the regular antibodies in the 
plasma fraction of whole blood usually were not associated 
with significant antigen-antibody reactions. It would thus be 
inconsistent to think that an irregular antibody having a lower 
serum concentration than a regular antibody can produce 
transfusion reactions in a recipient, given the percentage of 
plasma present in a unit of RBCs (which is less than 5%28 and is 
diluted in preservative solution), which is the most transfused 
component. Otherwise, transfusion of group O blood to group 
A or B patients would be considered unacceptable.29 Although 
these antibodies are transfused, they can adsorb to antigens 
located in different organs (e.g., endothelium, liver) because 
their expression is not limited to RBCs, reducing the chances 
of HTR or exposure to circulating RBCs.
To test this hypothesis, a study was conducted that 
determined regular antibodies’ agglutination capacity in 
supernatant from packed RBC units obtained from our blood 
bank. We were unable to demonstrate any agglutination despite 
including an indirect antiglobulin test for regular antibodies 
in the RBC supernatant whose ABO groups were known 
(data not shown). The data shown in Tables 3 to 5 reflecting 
calculations of the probability of antigen-antibody reaction, 
along with the traditional practice of transfusion, showed a low 
probability as a result of transfusion of plasma components, as 
has been shown in other studies.30–32 Then, even if transfused 
(fresh-frozen plasma, RBC units, platelets, or cryoprecipitates), 
these antibodies will be unlikely to cause recipient hemolysis 
because they will be diluted in the recipient’s circulation.33–36
As shown in Tables 3 through 6, the likely number of 
antigen-antibody reactions per year was significantly higher 
in the calculations involving the components obtained from 
women than those from men. If the analysis is performed 
separately for men and women for the transfusion of RBC units 
(Table 6), the probable number of events per year for anti-D, 
-K, -E, -M, and -S is 23.99 cases per year (women) versus 
4.68 cases per year (men). However, as mentioned previously, 
because the content of plasma in RBC units is very low and the 
dilution in the intravascular compartment is high, the overall 
effect may be negligible.
Special Considerations
With respect to the resistance to irregular antibody 
screening in platelet donors, it is necessary to emphasize 
that the problem of rejection and platelet alloimmunization 
is attributable mostly to the presence of anti-HLA antibodies, 
antineutrophil antibodies, and antiplatelet glycoprotein 
antibodies,37 which are found in 30 percent of women not 
transfused but with a history of pregnancy,38,39 and 66 percent 
of women with a history of transfusion and pregnancy.40 
Not all of them correspond to RBC antibodies, and therefore 
they are not routinely screened for in blood banks. Therefore, 
performing a routine RBC antibody screen is of little value. 
Additionally, although transfused plasma could have RBC 
antibodies, they are distributed throughout the available 
intravascular fluid and eventually join a fraction of these 
RBC receptors. However, because there is a much larger 
number of RBCs than RBC antibodies, the rate of antibody-
antigen reaction is limited by the antibody provided, which 
has been processed at temperatures between 18° and 23°C, 
which reduces its activity.41,42 Thus, the proposal to remove 
the screening of irregular antibodies will neither increase 
the number of cases of HTR nor reduce RBC survival in this 
population.
In emergency transfusion situations and massive 
transfusions such as patients with hemorrhagic shock who 
need immediate blood transfusion, there is no time for the 
blood bank to perform antibody screening tests; under these 
circumstances the risk of transfusing group O uncrossmatched 
RBCs is very low and is lower than the risk of the patient’s 
death if a blood transfusion is delayed.43
These data, taken together with that presented by other 
authors,7,12,13,18,19,44 demonstrated the low frequency of such 
AAs in the blood donor population and called into question this 
measure’s usefulness regarding its cost as a routine procedure.
Conclusion
The data presented above do not represent strong support 
for the routine screening for AAs in blood donors. It is thus 
proposed that the Colombian blood donor population should 
not be subjected to routine AA screening; instead, we suggest 
that all Colombian blood banks adopt the Colombian Red Cross 
policy of discarding female plasma, thus withdrawing from 
the market four of five units that could theoretically contribute 
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to antigen-antibody reaction. AA screening in donors is only 
useful if the recipient’s phenotype has been ascertained. This 
should only be done for those who need long-term blood 
transfusions and who clearly have high CSAA frequency.44 
AA screening is not clinically significant in patients who are 
only transfused once. Colombia is a country having limited 
resources, and public health assets should be adjusted to 
the population. Evidence-based strategies for redistributing 
existing resources should therefore be implemented. These 
would avoid annual resources being inappropriately used on 
screening that does not prevent HTR reactions or shortened 
RBC survival in 99.96 percent of cases.
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